Starbucks Stock Falls 19% in 6 Months: Time to Buy or Stay Away?

Starbucks (SBUX) shares have significantly underperformed, dropping 18.6% over six months, driven by persistent weakness in its core U.S. market, which saw a 2% decline in comparable sales and a 45% year-over-year EPS contraction in Q3 FY25. Analyst sentiment has soured, with 2025 and 2026 EPS estimates recently cut by over 6%, while operating margins also contracted. Despite some international strength and ongoing turnaround efforts, the stock's elevated 33.99x forward P/E valuation amid an uncertain domestic recovery and a Zacks Rank #4 (Sell) position suggests caution for investors.

Analysis

Starbucks is facing significant fundamental headwinds, reflected in its 18.6% stock price decline over the past six months, a stark underperformance against the S&P 500's 7.4% gain. The core of the issue lies in its domestic U.S. market, which experienced a 2% drop in comparable sales and a nearly 4% decline in transaction volumes in the third quarter of fiscal 2025. This weakness has directly impacted profitability, leading to a 660 basis point contraction in operating margin to 10.1% and a severe 45% year-over-year fall in earnings per share. Analyst sentiment has turned bearish, with consensus EPS estimates for 2025 and 2026 being revised downward by 11.2% and 6.8% respectively in the last 30 days. Compounding these issues is a demanding valuation; the stock trades at a forward P/E of 33.99x, a premium to both the industry and peers like McDonald's and Chipotle, which are forecasting positive earnings growth. While bright spots exist in the form of record international revenue and a strong digital member base of nearly 34 million, the company's recovery hinges on the uncertain and costly 'Back to Starbucks' turnaround plan, for which management has provided a conservative and unpredictable outlook.

Key Decisions for Investors

• Given the deteriorating U.S. fundamentals, downward EPS revisions, and significant stock underperformance, a cautious or underweight position is warranted until tangible signs of a domestic recovery appear.
• The stock's premium forward P/E ratio of 33.99x presents a considerable valuation risk, and investors should be wary of potential multiple compression if operational metrics do not improve.
• Investors should closely monitor upcoming reports for a stabilization or reversal in U.S. comparable sales and transaction volumes, as these are the primary indicators for gauging the success of the company's turnaround initiatives.